Sugi Predict

Sugi Predict / Compounds / SCHEMBL21426239

SCHEMBL21426239

SCHEMBL21426239

CN1CCC(n2cc(B3OC(C)(C)C(C)(C)O3)cn2)C1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.42
▸ FLT4 P35916 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ GAA P10253 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ NAMPT P43490 1/20 0.32
▸ ALOX15 P16050 1/20 0.31
▸ GSK3B P49841 2/20 0.31
▸ DYRK1A Q13627 2/20 0.31
▸ IRAK4 Q9NWZ3 3/20 0.31
▸ USP30 Q70CQ3 1/20 0.31
▸ FLT3 P36888 1/20 0.31
▸ MPO P05164 1/20 0.31
▸ MELK Q14680 1/20 0.31
▸ TLR7 Q9NYK1 1/20 0.31
▸ RORC P51449 1/20 0.31
▸ WNT1 P04628 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL28336982 0.97 FFAR1 (0.43) FFAR1FLT4KDRGAASMN1; SMN2
SCHEMBL29339810 0.92 FFAR1 (0.40) FFAR1FLT4KDRUSP30MELK
SCHEMBL657486 0.92 FFAR1 (0.44) FFAR1GAASMN1; SMN2ALOX15GSK3B
SCHEMBL21318865 0.89 FFAR1 (0.46) FFAR1IRAK4MPO
SCHEMBL21588639 0.89 FFAR1 (0.40) FFAR1GAASMN1; SMN2ALOX15GSK3B
SCHEMBL30566117 0.86 FFAR1 (0.41) FFAR1GSK3BDYRK1AIRAK4FLT3
SCHEMBL1987497 0.84 FFAR1 (0.49) FFAR1IRAK4USP30MPO
SCHEMBL9100609 0.83 FFAR1 (0.43) FFAR1GSK3BDYRK1AIRAK4MPO
SCHEMBL28649940 0.83 FFAR1 (0.46) FFAR1USP30MPO
SCHEMBL2572488 0.82 FFAR1 (0.47) FFAR1IRAK4MPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270213-A1 PI3Ka INHIBITORS PIKAVATION THERAPEUTICS, INC. 2025-08-28 — — US disclosed
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-04-10 — — US disclosed
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-02-20 — — US disclosed
EP-4452977-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 — — EP disclosed
EP-4452978-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 — — EP disclosed
EP-3632907-B1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2024-02-28 — — EP disclosed
EP-3632907-B1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2024-02-28 — — EP disclosed
WO-2023115142-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 — — WO disclosed
WO-2023115142-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 — — WO disclosed
WO-2023115150-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 — — WO disclosed
WO-2023115150-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 — — WO disclosed
US-11149021-B2 N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-10-19 — — US disclosed
US-11149021-B2 N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-10-19 — — US disclosed
CN-110573500-B N- (nitrogen heterocyclic aryl) lactam-1-formamide derivative and preparation method and application thereof 上海和誉生物医药科技有限公司 2020-12-08 — — CN disclosed
EP-3632907-A1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-08 — — EP disclosed
EP-3632907-A1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-08 — — EP disclosed
US-20200071302-A1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-03-05 — — US disclosed
US-20200071302-A1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-03-05 — — US disclosed
CN-110573500-A N- (nitrogen heterocyclic aryl) lactam-1-formamide derivative and preparation method and application thereof 上海和誉生物医药科技有限公司 2019-12-13 — — CN disclosed
WO-2018214867-A9 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海和誉生物医药科技有限公司 2019-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071302-A1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF CSF1R, CSF3R, FAR1 FFAR1 7/4885FLT4 1733/4885KDR 1173/4885
US-11149021-B2 N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof CSF1R, CSF3R, FAR1 FFAR1 7/4885FLT4 1733/4885KDR 1173/4885
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 FFAR1 1395/4885FLT4 1570/4885KDR 2442/4885
US-20250270213-A1 PI3Ka INHIBITORS PIK3CA, PIK3C2A, PIK3R5 FFAR1 3116/4885FLT4 1094/4885KDR 865/4885
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 FFAR1 950/4885FLT4 1088/4885KDR 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.